These five ETFs could be excellent choices for long-term investors. You don’t have to buy all of them, but if you have $1,000 available for investment, any one of these would make a wise initial step. Keep in mind that $1,000 is just a starting point; it’s beneficial to regularly invest in ETFs every month over the long term.
As an ardent follower of the market, I was intrigued when I noticed Navitas’ stock surge following their announcement about reporting earnings on August 4th. It wasn’t so much about what they would report as it was the simple fact that they were reporting at all. Surprisingly, investors are snapping up shares left and right, not knowing whether the upcoming earnings news will bring good or bad tidings. This unexpected enthusiasm is a fascinating study in market dynamics!
The surge in Plug Power’s stock price can be easily explained: This morning, Biju Perincheril from Susquehanna upped his price target for Plug stock by a significant 80%, raising it from $1 per share to $1.80. However, the real question is whether this single analyst’s opinion justifies a 8.1% increase in Plug Power’s stock price.
During the second quarter of 2025, Redhawk Wealth Advisors boosted its ownership in Invesco QQQ Trust Series 1 (QQQ) by purchasing an additional 7,181 shares, as reported in a filing made to the Securities and Exchange Commission on July 10, 2025. The deal was worth approximately $3.57 million, resulting in the fund owning a total of 18,597 QQQ shares by June 30, 2025. By July 21, 2025, this holding had increased to a value of around $10.44 million.
The company that thrived during the real estate boom caused by the pandemic has now failed, due to rising interest rates and a struggling housing market. Many homeowners who took advantage of low mortgage rates during the pandemic are hesitant to sell their properties, leading to a decline in the business. This stock has plummeted, with its value dropping 96% from its highest point in 2021.
In my observation, we’ve arrived at Rhythm Pharmaceuticals (RYTM), a mid-sized biotech company, causing quite a stir in the broader weight loss market. Specifically, it’s making waves within a particular subsector. Notably, this company just announced promising outcomes that significantly boosted its stock value. So, is this an enticing investment opportunity given these recent advancements? Let’s delve deeper to find out.
In a similar vein, previous successes don’t ensure future outcomes. So, let’s examine potential growth trajectories for XRP in the coming three years and consider key elements that might further escalate its value.
1. Pfizer could grow substantially within the oncology market, which currently holds the largest share of industry sales.
2. Novo Nordisk is expected to maintain a strong presence in diabetes care and the rapidly expanding weight management sector.
3. Both companies are likely to achieve impressive results during this period.
Considering the views of Wall Street analysts might offer some insight. Many who follow a small biotech firm named Iovance Biotherapeutics (IOVA) are optimistic about its stock. The company experienced a 52-week low of $1.64 just a few weeks back, but it has since seen a slight recovery. At the current price of $2.23 per share, the average price target of $10.70 (as reported by Yahoo! Finance) suggests a potential increase of approximately 380%.
It appears that 2025 could mark a significant point in Apple’s journey as they explore fresh avenues for expansion. However, whether this calls for buying or selling the stock prior to their July 31 earnings isn’t straightforward. A definitive answer can be gleaned by closely examining the financial data.